抗体药物复合体(ADC)契约製造市场规模、份额和成长分析（按研发阶段、製程组件、标靶适应症、抗体生成、抗体来源和地区划分）－2026-2033 年产业预测

全球抗体药物复合体(ADC)契约製造市场规模预计在 2024 年达到 96.4 亿美元，从 2025 年的 108.1 亿美元增长到 2033 年的 269.5 亿美元，在预测期（2026-2033 年）内复合年增长率为 12.1%。

全球抗体药物复合体(ADC)契约製造市场正经历显着成长，这主要得益于对标靶癌症疗法的需求不断增长以及生物製药研发的进步。癌症发生率的上升促使精准医疗成为重要的治疗手段，而 ADC 也因此成为关键的治疗手段。生技製药和生技公司不断增加研发投入，预计将进一步推动市场成长。此外，ADC 生产流程复杂，需要专业的生物偶联技术和先进的检测方法，这也创造了新的商机。同时，监管机构对创新 ADC 疗法的支持（例如加速核准程序）预计将推动对契约製造服务的需求。然而，高昂的生产成本、严格的监管、专业生产商的匮乏以及供应链问题等挑战可能会限制市场渗透率。

推动全球抗体药物复合体契约製造市场发展的因素

抗体药物复合体）治疗应用范围的不断扩大，正促使众多製药和生技公司加强研发投入。随着临床试验的推进，市场对能够提供扩充性且符合规范的生产能力的製造合作伙伴的需求日益增长。此外，全球核准的抗体药物复合体数量不断增加，预计将为专注于此类创新治疗方法契约製造的公司创造新的机会。这种动态情势表明，外包生产服务对于满足抗体药物复合体市场不断变化的需求至关重要。

限制全球抗体药物复合体契约製造市场的因素

由于抗体药物复合体）的设计、开发和生产流程复杂，全球契约製造市场面临许多限制因素。此类生产需要专门的设施，包括抗体生产、细胞毒性药物处理和偶联工艺，因此需要大量的资本投入。此外，检验安全性和有效性所需的大量临床前和临床试验导致研发高成本，这可能会在长期内抑制该领域对契约製造服务的需求。这些因素共同为市场相关人员带来了巨大的挑战。

全球抗体药物复合体契约製造市场趋势

全球抗体药物复合体）契约製造市场正呈现出显着趋势，这主要得益于主要企业之间的策略联盟和产能扩张。为了提高营运效率并降低供应链中断的风险，各公司越来越多地与製药创新者合作，以确保获得专属的生产资源，从而简化生产流程。这种合作模式不仅有助于消除瓶颈，也凸显了市场对灵活生产解决方案日益增长的需求。随着医疗保健产业的不断发展，扩充性和柔软性日益受到重视，这一市场趋势被视为持续增长的基础，并有助于提供先进的治疗药物以满足不断增长的全球需求。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 原料分析

全球抗体药物复合体（ADC）契约製造市场规模（按研发阶段和复合年增长率划分）（2026-2033 年）

• 第一阶段
• 第二阶段
• 第三阶段

全球抗体药物复合体（ADC）契约製造市场规模（按生产流程和复合年增长率划分）（2026-2033 年）

• 抗体
• 高毒性强效药物（HPAPI）/细胞毒性有效载荷
• 键/连接体
• 填充和精加工

全球抗体药物复合体（ADC）契约製造市场规模（按目标适应症和复合年增长率划分）（2026-2033 年）

• 固态肿瘤
• 血液肿瘤
• 其他的

全球抗体药物复合体(ADC)契约製造市场规模（以抗体代数和复合年增长率划分）（2026-2033 年）

• 第二代
• 第三代
• 第四代
• 新一代

全球抗体药物复合体(ADC)契约製造市场规模（按抗体来源和复合年增长率划分）（2026-2033 年）

• 人源化抗体
• 嵌合体体
• 小鼠衍生
• 其他的

全球抗体药物复合体(ADC)契约製造市场规模（按连接子类型和复合年增长率划分）（2026-2033 年）

• 马来酰亚胺
• SMCC
• 四肽连接子
• 缬氨酸-瓜氨酸
• 其他的

全球抗体药物复合体（ADC）契约製造市场规模（按最终用户划分）及复合年增长率（2026-2033 年）

• 製药公司
• 生技公司 - 30%
• 学术和研究机构
• 其他的

全球抗体药物复合体（ADC）契约製造市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Lonza Group AG（Switzerland）
• WuXi XDC（China）
• Catalent, Inc.（USA）
• Piramal Pharma Solutions（India）
• MilliporeSigma（Germany）
• Sterling Pharma Solutions（UK）
• AGC Biologics（USA）
• Cerbios-Pharma SA（Switzerland）
• CARBOGEN AMCIS（Switzerland）
• Curia（USA）
• Abzena PLC（UK）
• WuXi Biologics（Cayman Islands）
• Ajinomoto Bio-Pharma Services（Japan）
• Axplora（France）
• Sartorius AG（Germany）
• Samsung Biologics（South Korea）
• Recipharm AB（Sweden）
• AbbVie Contract Manufacturing（USA）
• Formosa Laboratories（Taiwan）
• Veranova（USA）

结论与建议

Global Antibody Drug Conjugates Contract Manufacturing Market size was valued at USD 9.64 Billion in 2024 and is poised to grow from USD 10.81 Billion in 2025 to USD 26.95 Billion by 2033, growing at a CAGR of 12.1% during the forecast period (2026-2033).

The global market for antibody drug conjugates (ADCs) contract manufacturing is experiencing significant growth driven by the rising demand for targeted cancer therapies and advancements in biologics research and development. As cancer prevalence increases, there is a notable shift towards precision medicine, positioning ADCs as a key treatment approach. Enhanced investments in R&D by biopharma and biotech firms are anticipated to further propel market expansion. Additionally, the complexity of ADC manufacturing processes-necessitating specialized bioconjugation techniques and advanced testing methods-opens up new business opportunities. Meanwhile, regulatory support for innovative ADC therapies through expedited approvals is expected to elevate demand for contract manufacturing services. However, challenges such as high production costs, stringent regulations, limited specialized manufacturers, and supply chain issues may restrict market penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Drug Conjugates Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Drug Conjugates Contract Manufacturing Market Segments Analysis

Global Antibody Drug Conjugates Contract Manufacturing Market is segmented by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User and region. Based on Stage of Development, the market is segmented into Phase I, Phase II and Phase III. Based on Process Component, the market is segmented into Antibody, HPAPI / Cytotoxic Payload, Conjugation / Linker and Fill / Finish. Based on Target Indication, the market is segmented into Solid Tumors, Hematological Tumors and Others. Based on Antibody Generation, the market is segmented into Second Generation, Third Generation, Fourth Generation and Next Generation. Based on Antibody Origin, the market is segmented into Humanized, Chimeric, Murine and Others. Based on Type of Linker, the market is segmented into Maleimide, SMCC, Tetrapeptide-based linker, Valine-citrulline and Others. Based on End User, the market is segmented into Pharmaceutical Companies, Biotechnology Companies - 30%, Academic & Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibody Drug Conjugates Contract Manufacturing Market

The expanding therapeutic applications of various antibody drug conjugates have spurred significant investments in research and development from numerous pharmaceutical and biotechnology firms. As clinical trials advance, the demand for manufacturing partners that can provide scalable and compliant production capabilities has intensified. Furthermore, the rising approvals of antibody drug conjugates globally are anticipated to generate fresh opportunities for companies specializing in contract manufacturing of these innovative therapies. This dynamic landscape underscores the growing importance of outsourcing manufacturing services in order to meet the evolving needs of the antibody drug conjugate market.

Restraints in the Global Antibody Drug Conjugates Contract Manufacturing Market

The global market for antibody drug conjugates contract manufacturing faces notable constraints due to the complexity of its design, development, and production processes. This manufacturing requires specialized facilities dedicated to antibody production, the handling of cytotoxic drugs, and the conjugation process, which demands substantial capital investment. Additionally, the high costs associated with research and development, driven by extensive preclinical and clinical testing necessary to verify safety and efficacy, are likely to hinder demand for contract manufacturing services in this field over time. These factors collectively create significant challenges for stakeholders involved in the market.

Market Trends of the Global Antibody Drug Conjugates Contract Manufacturing Market

The Global Antibody Drug Conjugates Contract Manufacturing market is witnessing a significant trend driven by strategic collaborations and capacity expansions among key players. To enhance operational efficiency and mitigate potential supply chain disruptions, companies are increasingly partnering with pharmaceutical innovators, securing dedicated manufacturing slots that streamline production processes. This focus on collaboration not only addresses bottlenecks but also underlines a growing demand for adaptable manufacturing solutions. As healthcare continues to evolve, the emphasis on scalability and flexibility positions this market trend as a cornerstone of sustained growth, facilitating the delivery of advanced therapeutics to meet rising global demand.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Raw Material Analysis

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Stage of Development & CAGR (2026-2033)

• Market Overview
• Phase I
• Phase II
• Phase III

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Process Component & CAGR (2026-2033)

• Market Overview
• Antibody
• HPAPI / Cytotoxic Payload
• Conjugation / Linker
• Fill / Finish

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Target Indication & CAGR (2026-2033)

• Market Overview
• Solid Tumors
• Hematological Tumors
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Antibody Generation & CAGR (2026-2033)

• Market Overview
• Second Generation
• Third Generation
• Fourth Generation
• Next Generation

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Antibody Origin & CAGR (2026-2033)

• Market Overview
• Humanized
• Chimeric
• Murine
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Type of Linker & CAGR (2026-2033)

• Market Overview
• Maleimide
• SMCC
• Tetrapeptide-based linker
• Valine-citrulline
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies - 30%
• Academic & Research Institutes
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size & CAGR (2026-2033)

• North America (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • US
  • Canada
• Europe (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi XDC (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Pharma Solutions (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MilliporeSigma (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sterling Pharma Solutions (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cerbios-Pharma SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CARBOGEN AMCIS (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abzena PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (Cayman Islands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ajinomoto Bio-Pharma Services (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axplora (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Contract Manufacturing (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Formosa Laboratories (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veranova (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations